Skip Nav Destination
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model
Comparison of gene expression profiles between human and mouse monocyte subsets
Issue Archive
January 21 2010
In this Issue
Table of Contents
INSIDE BLOOD
PLENARY PAPERS
REVIEW ARTICLES
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan K. Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield
CLINICAL TRIALS AND OBSERVATIONS
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
Clinical Trials & Observations
Nicholas Di Bella,Raymond Taetle,Kathryn Kolibaba,Thomas Boyd,Robert Raju,David Barrera,Ernest W. Cochran, Jr,Philip Y. Dien,Roger Lyons,Peter J. Schlegel,Svetislava J. Vukelja,Julie Boston,Kristi A. Boehm,Yunfei Wang,Lina Asmar
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study
Clinical Trials & Observations
Benilde Cosmi,Cristina Legnani,Alberto Tosetto,Vittorio Pengo,Angelo Ghirarduzzi,Sophie Testa,Domenico Prisco,Daniela Poli,Armando Tripodi,Francesco Marongiu,Gualtiero Palareti,for the PROLONG Investigators (on behalf of Italian Federation of Anticoagulation Clinics)
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
Clinical Trials & Observations
John C. Byrd,Thomas J. Kipps,Ian W. Flinn,Januaro Castro,Thomas S. Lin,William Wierda,Nyla Heerema,James Woodworth,Steve Hughes,Shabnam Tangri,Sarah Harris,Dee Wynne,Arturo Molina,Bryan Leigh,Susan O'Brien
GENE THERAPY
HEMATOPOIESIS AND STEM CELLS
Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development
Xiaoming Feng,Gregory C. Ippolito,Lifeng Tian,Karla Wiehagen,Soyoung Oh,Arivazhagan Sambandam,Jessica Willen,Ralph M. Bunte,Shanna D. Maika,June V. Harriss,Andrew J. Caton,Avinash Bhandoola,Philip W. Tucker,Hui Hu
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
Aldo M. Roccaro,Antonio Sacco,Emanuel N. Husu,Costas Pitsillides,Steven Vesole,Abdel Kareem Azab,Feda Azab,Molly Melhem,Hai T. Ngo,Phong Quang,Patricia Maiso,Judith Runnels,Mei-Chih Liang,Kwok-Kin Wong,Charles Lin,Irene M. Ghobrial
MYELOID NEOPLASIA
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia
Ion Cristóbal,Francisco J. Blanco,Laura Garcia-Orti,Nerea Marcotegui,Carmen Vicente,José Rifon,Francisco J. Novo,Eva Bandres,María J. Calasanz,Carmelo Bernabeu,María D. Odero
DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model
Brief Report
Kouichi Furugaki,Katerina Pokorna,Carole Le Pogam,Masayuki Aoki,Murielle Reboul,Véronique Bajzik,Patricia Krief,Anne Janin,Marie-Elena Noguera,Robert West,Dominique Charron,Christine Chomienne,Marika Pla,Hélène Moins-Teisserenc,Rose Ann Padua
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Comparison of gene expression profiles between human and mouse monocyte subsets
e-blood
Molly A. Ingersoll,Rainer Spanbroek,Claudio Lottaz,Emmanuel L. Gautier,Marion Frankenberger,Reinhard Hoffmann,Roland Lang,Muzlifah Haniffa,Matthew Collin,Frank Tacke,Andreas J. R. Habenicht,Loems Ziegler-Heitbrock,Gwendalyn J. Randolph
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
VASCULAR BIOLOGY
CORRESPONDENCE
-
Cover Image
Cover Image
This figure depicts a plausible model for the mode of autoantibody binding to β2GPI antigen. Platelet factor 4 tetramer binds to β2GPI, promoting the natural dimerization of the latter. Upon dimerization of β2GPI, the epitopes—that thrombosis-associated antibodies recognize on domain I—are arranged in a geometry that precisely fits to the 2 antigen-binding sites of an antibody, allowing their bivalent recognition by low-affinity autoantibodies. On the opposite site of the β2GPI-PF4 complex, positively charged patches in domain V of β2GPI are involved in interaction with negatively charged membranes. See article by Sikara et al on page 713.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement